# **Special Issue**

## Novel Vaccines and Vaccine Technologies for Emerging Infections

### Message from the Guest Editors

This Special Issue aims to provide a platform for sharing the most recent advances in the development of novel vaccine candidates, platforms, and technologies for combating emerging infections and future pandemics. More specifically, we welcome the contribution of original research articles, reviews, and commentaries that address the following topics:

- New vaccine platforms, technologies, and adjuvants;
- Universal vaccine candidates:
- Mucosal vaccines and vaccination:
- Modular vaccine platforms for rapid biomanufacturing and expedited regulatory approval;
- Vaccines as a tool for antimicrobial resistance;
- Al application in the rapid identification of novel vaccine antigens;
- Immune correlates of vaccine-induced protection;
- Systems immunology and vaccinology;
- Novel in vitro and in vivoassays and models for assessing vaccine-induced immunity and predicting vaccine efficacies;
- Vaccine bioprocess and manufactures.

### **Guest Editors**

Prof. Dr. Wangxue Chen

Dr. Xuguang Li

Prof. Dr. Amine A. Kamen

## Deadline for manuscript submissions

closed (30 September 2025)



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/183532

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

#### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

#### **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

